Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NaV1.8 Inhibitors (VX-150, Suzetrigine, VX-993) Mechanistic Study in Healthy Adults
NCT06420765Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- May 2024
- Primary completion
- Mar 2025
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VX-150, suzetrigine and VX-993 in pain (4 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Change From Baseline in Activity Dependent Slowing. Started May 2024; status: completed.
02
Drugs
VX-150suzetrigineVX-993
03
Conditions
pain
Beyond the preview
Go deeper on NCT06420765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06420765.